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PreviewspRCC-2, mutations in FH have not been
detected in sporadic pRCC-2, and spo-
radic pRCC-2 tumors do not accumulate
succinated proteins (Bardella et al.,
2011). Thus, how antioxidant genes are
upregulated in sporadic pRCC-2 remains
unclear.
The contribution of antioxidant genes
to renal tumorigenesis in patients with
HLRCC requires further exploration. How-
ever, there is precedent implicating Keap1
and Nrf2 in tumor development. Somati-
cally acquired loss-of-function KEAP1
mutations have been found in tumors (Ta-
guchi et al., 2011). Nrf2 is also stabilized
in tumors by mutation in either of the two
motifs involved in Keap1 binding that are
necessary for its degradation (Taguchi
et al., 2011). Consistent with the notion
that these two proteins function in
concert, mutations in KEAP1 and NRF2
tend not to be observed together in the
same tumor (Taguchi et al., 2011).
Understanding the biology of HLRCC-
associated pRCC-2 will hopefully lead to
new therapies. Because FH is lost in
tumor cells, and this truncates the TCA
cycle, these tumors may be exquisitely
dependent on glycolysis for energy
generation. As determined by 2-deoxy-
2-(18F)fluoro-D-glucose (FDG) positron
emission tomography (PET), FH-deficient420 Cancer Cell 20, October 18, 2011 ª2011tumors take up large amounts of glucose
(Yamasaki et al., 2011). Although exploit-
ing this dependency may be challenging
(Yamasaki et al., 2011), this may offer an
opportunity for therapeutic intervention.
Recently, HMOX1, which is required
for heme synthesis and is upregulated in
FH-deficient tumors, was proposed as a
therapeutic target (Frezza et al., 2011).
FH-deficient cells maintain segmental
TCA cycle function and NADH generation
by using glutamine and disposing of
excess carbon through the synthesis of
heme and its excretion from the cell as
bilirubin (Frezza et al., 2011). Interestingly,
inhibition of HMOX1 is synthetically lethal
with FH deficiency. However, the selec-
tivity of this approach in patients remains
to be determined, particularly because
HLRCC patients are heterozygous for
FH, and mutant FH may be incorporated
into FH homotetramers, markedly re-
ducing FH activity in non-neoplastic cells.
Nonetheless, this concept deserves to be
studied further in primary xenografts and,
subsequently, in patients.
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Reports of whole-exome sequencing in myelodysplastic syndrome (MDS) patients by Yoshida et al. and
Papaemmanuil et al. suggest spliceosome mutations have clinical relevance. Identifying the impact of these
mutations on MDS pathogenesis holds promise for therapeutic modulation of mRNA splicing.The myelodysplastic syndromes (MDSs)
are a heterogeneous group of myeloid
malignancies characterized by clonal he-
matopoiesis, impaired differentiation, pe-
ripheral blood cytopenias, and increasedrisk of progression to acute myeloid leu-
kemia. Although recent studies have iden-
tified recurrent somatic mutations in most
patients with MDS, approximately 20% of
patients with MDS had no known somaticgenetic or cytogenetic abnormalities in
the largest studies to date. Two recent
studies report the results of whole-exome
sequencing in patients with MDS (Pa-
paemmanuil et al., 2011; Yoshida et al.,
Figure 1. The Spliceosome and Mutations in Multiple Members of Genes Encoding Spliceosomal Proteins
Five small ribonuclear protein particles (snRNPs) and over 50 accessory proteins are assembled at the exon/intron junction of pre-mRNA to form the spliceosome.
The U1 snRNP binds to the 50 splice site through base pairing between the splice site and the U1 snRNA. The branchpoint, required for the lariat intermediate, is
bound by SF1, whereas the polypyrimidine tract is bound by the large subunit of U2AF (U2AF65). The small subunit of U2AF (U2AF35) binds to the AG at the 30
splice site. TheWWdomain protein PRPF40B is thought to bind SF1 and serve in early spliceosome assembly, but its functions are not well understood. Following
U1 snRNP and U2AF assembly, the U2 snRNP, the U4-6 tri-snRNP, and other splicing factors are assembled sequentially to form the spliceosome. SF3B1 and
SF3A1 are components of U2 snRNP, and it is thought that they bind pre-mRNA upstream of the intro branch site in a sequence-independent manner to anchor
the U2 snRNP to pre-mRNA. Members of the SR protein family bind to a nearby exonic-splicing enhancer region to directly recruit splicing machinery through
physical interactions with U2AF35 and ZRSR2 (a homolog of U2AF35). This interaction is critical in defining exon/intron boundaries. Members of the spliceosomal
complex found to be mutated in myeloid malignancies are indicated in red in (A) and described in (B). ALL, acute lymphoblastic leukemia; CLL, chronic lympho-
cytic leukemia; CMML, chronicmyelomonocytic leukemia;MPN,myeloproliferative neoplasms; NHL, non-Hodgkin lymphoma; RARS, refractory anemia with ring
sideroblasts; RCMD-RS, refractory-cytopenia with multilineage dysplasia and ring sideroblasts; sAML, secondary AML; t-MDS, therapy-related MDS. In foot-
note 1, ‘‘’’ indicates no mutations found, and ‘‘nd’’ indicates sequencing not done. In footnote 2, only regions of recurrent mutations were sequenced in these
lymphoid malignancies.
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Previews2011). Notably, themost frequent novel re-
currentmutations found occurred in genes
encoding members of the RNA-splicing
machinery (Figure 1).
The paradigm that alterations in
splicing contribute to the pathogenesis
of human disease and promote tumori-
genesis is well described. However, the
majority of disease-associated splicing
abnormalities discovered previously were
in cis-acting elements that disrupt splice-site selection at specific loci. By contrast
the Papaemmanuil et al. (2011) and Yosh-
ida et al. (2011) reports identified muta-
tions in the trans-acting members of the
spliceosome necessary for processing
pre-mRNA to mature mRNA. The genetic
data supporting these mutations as dis-
ease alleles are compelling; the majority
of the mutations in SF3B1 and all of the
mutations in U2AF35 and SRSF2 are
recurrent, heterozygous point mutations,Cancer Cell 20suggesting a gain of function conferred
by these recurrent mutations (Figure 1).
In contrast rarer mutations in ZRSR2 and
PRPF40B occurred as missense or non-
sense mutations, suggesting that these
mutations might result in loss of function.
In addition, Yoshida et al. (2011) found
that spliceosomal gene mutations are
largely mutually exclusive of one another,
consistent with a general role of spliceo-
some mutations in MDS pathogenesis., October 18, 2011 ª2011 Elsevier Inc. 421
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PreviewsIn order to understand the spectrum
of spliceosomal gene mutations, both
groups also sequenced a spectrum of
myeloid malignancies in addition to MDS.
These data led both groups to note a
striking association between SF3B1 mu-
tations and MDS characterized by the
presence of ring sideroblasts (RS). Al-
though rare SF3B1 mutations have been
reported previously in epithelial cancers
derived from pancreas (Pleasance et al.,
2010), breast (Wood et al., 2007), and
ovary (Wood et al., 2007), SF3B1 muta-
tions occur in the majority of patients
with MDS with RS and much less com-
monly in other hematologic malignan-
cies. Although mutations in the other
spliceosomal components were more
common in other subtypes of MDS, the
mutations appear to be most enriched in
myeloid malignancies with some compo-
nent of dysplasia, including MDS of all
subtypes and chronic myelomonocytic
leukemia. Papaemmanuil et al. (2011)
noted that mutations in SF3B1 in MDS
are associated with longer overall- and
leukemia-free patient survival. Given the
already-known favorable prognosis of
MDS with RS, studies to identify whether
the prognostic effect of these muta-
tions is independent of MDS histopatho-
logic findings are needed. Moreover,
previous reports noting splicing alter-
ations in hematologic malignancies, such
as the report of frequent missplicing of
GSK3b in CML (Abrahamsson et al.,
2009), will need reevaluation to determine
if these cancer-specific splicing alter-
ations result from somatic mutations in
the spliceosome.
To understand the biological conse-
quences of spliceosomal mutations in he-
matopoiesis, the authors overexpressed
wild-type and mutant forms of U2AF35
in LinSca1+c-Kit+ hematopoietic cells
from wild-type mice. Competitive trans-
plantation with similarly transduced con-
trol cells revealed a competitive disadvan-
tage with U2AF35mutant overexpression.
Further work to characterize the effects
of these mutations on other aspects
of hematopoietic stem cell function in-
cluding self-renewal, differentiation, and
leukemogenesis are needed. Moreover,
comparison of the biological effects of
expression of recurrent point mutations
with downregulation of expression may
be very helpful in understanding the
biological consequences of spliceosomal422 Cancer Cell 20, October 18, 2011 ª2011component alterations in neoplastic
transformation.
The mutations in the spliceosomal
complex in different myeloid malignan-
cies suggest that these proteins may
have distinct functions at different stages
of hematopoietic differentiation. Very little
is known about the expression of the
various Serine/Arginine-rich (SR) proteins
in normal andmalignant hematopoiesis or
about the function of the spliceosome
in normal hematopoietic development.
Numerous splicing factors have been tar-
geted for constitutional knockout in mice,
but these resulted in largely embryonic or
perinatal lethality. Conditional gene tar-
geting in a tissue-specific manner has
only been carried out for Srsf1 (Xu et al.,
2005) and Srsf2 (Ding et al., 2004) so far.
Mice with cardiac-specific deletion of
Srsf1 develop severe dilated cardiomyop-
athy, leading to death by 6–8weeks of life,
whereas cardiac-specific Srsf2 knockout
mice develop a milder cardiomyopathy
and have a relatively normal life span.
These results suggest that the SR pro-
teins fulfill specialized, nonredundant
functions.
Data arguing for a role of spliceosomal
components outside of pre-mRNA pro-
cessing have also come from in vivo
modeling. For instance, in vivo analysis
of Sf3b1 knockout mice identified genetic
intersection with Polycomb Group protein
loss, leading to the identification of mul-
tiple physical interactions between SF3B1
and members of the PRC1 complex and
the BCL6 corepressive complex (Isono
et al., 2005). Further work to analyze the
role of disordered PRC1 activity and
BCL6 activity in MDS-RS pathogenesis is
now warranted.
Yoshida et al. (2011) assessed the
effects of expressing U2AF35 in wild-
type and mutant forms on gene expres-
sion and showed that overexpression of
U2AF35 mutants led to a greater fre-
quency of transcripts with unspliced in-
trons and increased expression of mem-
bers of the nonsense-mediated decay
pathway. They concluded that U2AF35
mutations, and possibly other spliceoso-
mal pathway mutations, function in a
dominant-negative manner to inhibit nor-
mal splicing, a hypothesis requiring fur-
ther evaluation. Previous studies have
noted overexpression of SR family pro-
teins in epithelial cancers, and over-
expression of SR proteins (includingElsevier Inc.SRSF1 and SRSF2) leads to cellular trans-
formation ability in other cellular contexts;
as such, future studies will need to dissect
differences between the role of mutant
and wild-type spliceosome proteins in
oncogenic transformation.
Identification of splicing factor muta-
tions inMDSmayalsoprovide apossibility
for therapeutic intervention. An excel-
lent example comes from investigational
therapies for the hereditary disorder
Duchenne muscular dystrophy (DMD).
DMD most commonly results from muta-
tions in a repetitive domain of Dystrophin.
Mutations in this domain can be over-
come by ‘‘skipping’’ the mutated exon to
generate truncated functional dystrophin
protein. Amazingly, a strategy of deliv-
ering an antisense oligonucleotide to
block an enhancer of exon splicing of
the mutated exon and result in a stable
mRNA transcript and dystrophin gene
product has been utilized successfully in
early clinical trials (van Deutekom et al.,
2007). In addition, compounds that spe-
cifically target the SF3A/B subunits of
U2 snRNP to result in nuclear export
of intron-bearing precursors exist and
should be studied further to determine if
they interfere with the aberrant splicing
due to recurrent mutations in these sub-
units (Kaida et al., 2007). These data sug-
gest that these two studies have uncov-
ered a novel pathway of importance to
myeloid malignancies that may lead to
novel therapeutic approaches for patients
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